These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26862499)

  • 1. Novel insights in the management of sickle cell disease in childhood.
    Iughetti L; Bigi E; Venturelli D
    World J Clin Pediatr; 2016 Feb; 5(1):25-34. PubMed ID: 26862499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of sickle cell disease from childhood through adulthood.
    Kanter J; Kruse-Jarres R
    Blood Rev; 2013 Nov; 27(6):279-87. PubMed ID: 24094945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the Treatment of Sickle Cell Disease.
    Kapoor S; Little JA; Pecker LH
    Mayo Clin Proc; 2018 Dec; 93(12):1810-1824. PubMed ID: 30414734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Therapies for the Management of Sickle Cell Disease.
    Rai P; Ataga KI
    F1000Res; 2020; 9():. PubMed ID: 32765834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving outcomes in children with sickle cell disease: treatment considerations and strategies.
    Amid A; Odame I
    Paediatr Drugs; 2014 Aug; 16(4):255-66. PubMed ID: 24797542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric sickle cell disease: past successes and future challenges.
    Meier ER; Rampersad A
    Pediatr Res; 2017 Jan; 81(1-2):249-258. PubMed ID: 27706129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sickle cell disease: current treatment and emerging therapies.
    Neumayr LD; Hoppe CC; Brown C
    Am J Manag Care; 2019 Nov; 25(18 Suppl):S335-S343. PubMed ID: 31809007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging disease-modifying therapies for sickle cell disease.
    Carden MA; Little J
    Haematologica; 2019 Sep; 104(9):1710-1719. PubMed ID: 31413089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular therapy for sickle cell disease.
    Abraham A; Jacobsohn DA; Bollard CM
    Cytotherapy; 2016 Nov; 18(11):1360-1369. PubMed ID: 27421743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Will developments in allogeneic transplantation influence treatment of adult patients with sickle cell disease?
    Chakrabarti S; Bareford D
    Biol Blood Marrow Transplant; 2004 Jan; 10(1):23-31. PubMed ID: 14752776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sickle Cell Disease.
    Kunz JB; Tagliaferri L
    Transfus Med Hemother; 2024 Oct; 51(5):332-344. PubMed ID: 39371249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoietic stem cell transplantation for adult sickle cell disease in the era of universal donor availibility.
    Aslam HM; Yousuf S; Kassim A; Iqbal SM; Hashmi SK
    Bone Marrow Transplant; 2018 Nov; 53(11):1390-1400. PubMed ID: 29728697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
    Kassim AA; DeBaun MR
    Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sickle cell disease: current activities, public health implications, and future directions.
    Creary M; Williamson D; Kulkarni R
    J Womens Health (Larchmt); 2007 Jun; 16(5):575-82. PubMed ID: 17627395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years.
    Chaturvedi S; DeBaun MR
    Am J Hematol; 2016 Jan; 91(1):5-14. PubMed ID: 26547630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea (hydroxycarbamide) genotoxicity in pediatric patients with sickle cell disease.
    Rodriguez A; Duez P; Dedeken L; Cotton F; Ferster A
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27022. PubMed ID: 29512872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond.
    Egesa WI; Nakalema G; Waibi WM; Turyasiima M; Amuje E; Kiconco G; Odoch S; Kumbakulu PK; Abdirashid S; Asiimwe D
    Int J Pediatr; 2022; 2022():3885979. PubMed ID: 36254264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sickle cell disease in the older adult.
    Thein MS; Igbineweka NE; Thein SL
    Pathology; 2017 Jan; 49(1):1-9. PubMed ID: 27914684
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.